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Abstract  Pneumocystis  pneumonia  (PCP)  is  caused  by  the  fungus  Pneumocystis  jirovecii,  and
its incidence  has  been  on  the  rise  in  immunosuppressed  patients  without  HIV.
We performed  a  cross  sectional  study  in  patients  with  PCP  and  assessed  demographic,  clinical
presentation  and  outcome  measures  such  as  mechanical  ventilation  and  mortality  differences
between  HIV  and  non-HIV  patients.
The  two  groups  were  statistically  signiﬁcantly  different,  with  the  HIV  group  being  younger
(45.5 years  vs  55.9  years,  p-value  0.001)  and  mostly  composed  of  male  patients  (69%  vs  31%,
p-value <0.001).  Also,  the  HIV  patients  had  higher  percentage  of  respiratory  complaints  (90%  vs
68%, p-value  0.02)  and  lactate  dehydrogenase  elevation  (73%  vs  40%,  p-value  0.001).  In  contrast,
non-HIV patients  had  worse  outcomes  with  higher  incidence  of  invasive  mechanical  ventilation
(23% vs  46%,  p-value  0.005)  and  in-hospital  mortality  (13%  vs  37%,  p-value  0.002).
These results  reﬂect  the  literature  and  should  raise  awareness  to  a  potentially  fatal  medical
situation  of  increasing  incidence.
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neumocystis  pneumonia  (PCP)  is  a  respiratory  invasive
nfection  caused  by  Pneumocystis  jirovecii,  an  ubiquitous
ungus.1 It  is  transmitted  by  air  and  mostly  infects  immuno-
ompromised  patients.1 PCP  is  characterized  by  respiratory
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Table  1  Demographic  characteristics  of  both  HIV  and  non-HIV  groups:  total  of  129  patients  (75  with  HIV  diagnosis  and  54  with
immunosuppression  other  than  HIV).  There  was  a  signiﬁcant  difference  in  age  (45.5  years  vs  55.9  years,  p-value  0.001)  and
gender (preponderance  of  male  sex  --  69%  vs  31%,  p-value  <0.001).
Demographics  HIV  Non-HIV  Total  p-Value
Age  45.5  (11.5)  55.9  (13.7)  49.8  (13.4)  0.001
Gender (male)  69.1%  (56)  30.9%  (25)  62.8%  (81)  <0.001
Length of  stay  27.8  (22.6)  29.1  (18.2)  28.3  (20.8)  0.7
Total 75  54  
Table  2  Risk  factors  for  immunosuppression  in  non-HIV
patients:  the  most  frequent  was  drug  related  immunosup-
pression  (89%)  and  transplant  (74%),  followed  by  cancer
(32%),  malnutrition  (0.04%)  and  primary  immunodeﬁciency
(0.02%).  The  most  common  cancers  were  hepatocellular
carcinoma  and  hematological  (30%  each),  transplants  were
about half  renal  and  hepatic.  The  most  used  immunosuppres-
sive  drugs  were  corticosteroids  (50%)  mTOR  inhibitors  (44%)
and mycophenolate  mofetil  (33%).
Risk  factors  Total  (non-HIV)
Cancer  31.5%  (17)
Hepatocellular  carcinoma  5  (30%)
Hematological  (lymphoma/leukemia)  5  (30%)
Breast 2  (10%)
Others 5  (30%)
Transplant  74%  (40)
Renal 21  (52%)
Hepatic  19  (48%)
Immunosuppressive  drugs  88.9%  (48)
Corticosteroids  24  (50%)
mTOR inhibitors  21  (44%)
Mycophenolate  mofetil 16  (33%)


























































value  0.001)  and  gender  (preponderance  of  male  sex  --  69%Malnutrition  0.04%  (2)
omplaints  of  cough,  dyspnea,  but  also  tachycardia,  low
rade  fever  and  hypoxemia.1,2 Analytically,  elevated  levels
f  lactate  dehydrogenase  (LDH)  are  very  suggestive,  and  in
erms  of  radiographic  ﬁndings  there  is  a  broad  range  from
iffuse  inﬁltrate  to  nodules,  cysts  and  pneumothorax.1,2
iagnosis  is  made  by  detection  by  RT-PCR  of  the  fungus  in
ronchoalveolar  lavage  (BAL)  material.2 Treatment  is  usually
ith  trimethoprim/sulfamethoxazole  (TMP/SMX),  but  other
ptions  are  available.2,3 When  there  is  important  hypox-
mia  (PaO2 ≤  70  mmHg),  adjuvant  corticosteroids  may  be
dded.2,3
Immunosuppression  other  than  HIV  can  be  drug  related,
ue  to  lymph  and  myeloproliferative  disorders,  solid  tumors,
utoimmune  diseases,  solid  organ  and  hematologic  trans-
lant,  primary  immunodeﬁciency  and  severe  malnutrition.4
t  has  been  shown  that  these  patients  are  at  increasing  risk
or  PCP,  and  usually  the  clinical  presentation  is  abrupt  with
ast  evolution  to  respiratory  failure  and  higher  mortality
30--60%  versus  10--20%  in  HIV  patients).2,4 Treatment  is  the
ame,  but  despite  prophylaxis  being  well  established  for  HIV
atients  (with  lower  doses  to  TMP/SMX),  there  is  still  no




The  main  goal  is  to  assess  the  differences  between  HIV
nd  non-HIV  patients  with  PCP.
ethods
ross  sectional  retrospective  study  by  chart  review  of
atients  with  pneumocystis  pneumonia  admitted  to  a  single
ertiary-care  center  between  2011  and  2016.
Permission  was  obtained  to  review  data  retrospectively
n  the  basis  of  medical  record  review  from  the  Centro  Hos-
italar  Universitário  de  Lisboa  Central  Institutional  Review
oard.
Eligible  patients  were  18  years  or  older  and  identiﬁed
sing  an  ICD-9  code  for  pneumocystis  pneumonia.
The  electronic  medical  record  for  each  eligible  patient
as  reviewed  to  obtain  demographic  data,  length  of  stay,
IV  infection  and  its  status,  and  risk  factors  for  PCP.  PCP  was
haracterized  by  clinical  (respiratory  complaints  any,  fever
-  axillary  temperature  over  37.5 ◦C),  analytical  (hypox-
mia  in  blood  gas  analysis  with  PaO2 <80  mmHg,  leucocytes
alues  higher  than  11  ×  109/L  and  below  4.5  ×  109/L,  lac-
ate  dehydrogenase  (LDH)  >220  U/L  and  C-reactive  protein
CRP)  >5  mg/mL),  and  radiological  features  (any  of  the
CP  radiological  presentations  was  considered),  deﬁned
s  dichotomous  variables  (presence/absence),  as  well  as
eﬁnitive  versus  probable  diagnosis.  Outcomes  were  in-
ospital  mortality,  corticotherapy  use  and  need  for  either
nvasive  or  non-invasive  mechanical  ventilation.
Data  was  analyzed  with  mean  and  standard  deviation  (SD)
f  normally  distributed  and  with  median  and  Interquartile
ange  (IQR),  if  non-normally  distributed.  Student  t-test  was
erformed  for  continuous  variables,  and  chi  square  test  for
ichotomous  variables.  Multivariate  logistic  regression  was
one  to  account  for  confounding.  To  avoid  model  overﬁtting,
he  rule  of  ten  was  observed.  A  p  value  of  <0.05  was  con-
idered  to  be  signiﬁcant.  Analysis  was  conducted  in  Stata
StataCorp.  Stata  statistical  software:  release  14.  College
tation,  TX:  StataCorp  LP).
esults
 total  of  129  patients  were  included  --  75  with  HIV  diagnosis
nd  54  with  immunosuppression  other  than  HIV  (Table  1).
etween  these  2  groups  there  was  a  signiﬁcant  difference  in
emographic  data  mainly  age  (45.5  years  vs  55.9  years,  p-s  31%,  p-value  <0.001).  There  was  no  difference  between
IV  and  non-HIV  in  length  of  stay  (overall  mean  28.3  days  ±
0.8).
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Table  3  Clinical  characteristics  of  pneumocystosis  pneumonia:  statistically  signiﬁcant  difference  between  HIV  and  non-HIV
patients in  relation  to  respiratory  complaints  (90%  vs  68%,  p-value  0.02)  and  lactate  dehydrogenase  (LDH)  elevation  at  diagnosis
(73% vs  40%,  p-value  0.001).  There  was  no  statistically  signiﬁcant  difference  between  groups  in  the  presence  of  fever,  hypoxemia,
white blood  count  abnormalities  and  C-reactive  protein.  Deﬁnite  diagnosis  was  similar  in  both  groups  (81%  vs  73%,  p-value  =  0.4).
PCP  characteristics HIV  Non-HIV  Total  p-Value
Respiratory  complaints  90%  (67)  68%  (37)  81%  (104)  0.002
Fever 77%  (55)  68%  (36)  73%  (91)  0.2
Hypoxemia  (blood  gas)  85%  (61)  83%  (43)  84%  (104)  0.7
Leukocytosis/leukopenia  43%  (29) 35%  (17)  40%  (46)  0.4
LDH 73%  (48) 40%  (18) 60%  (66)  0.001
CRP 48%  (23) 53%  (25) 59%  (69) 0.17
Deﬁnite diagnosis 81%  (60) 87%  (47) 84%  (107) 0.4
Table  4  Outcomes  differences  between  HIV  and  non-HIV:  statistically  signiﬁcant  differences  observed  for  need  for  invasive
mechanical ventilation  (23%  vs  46%,  p-value  0.005)  and  in-hospital  mortality  (13%  vs  37%,  p-value  0.002).  There  was  no  statistically
signiﬁcant difference  in  the  need  for  corticotherapy  or  non-invasive  mechanical  ventilation.
Outcomes  HIV  Non-HIV  Total  p-Value
Corticotherapy  73%  (55)  73%  (37)  73%  (92)  0.9
Non-invasive  mechanical  ventilation  3%  (2)  7%  (4)  5%  (6)  0.2

























compare  time  to  diagnosis  in  the  two  settings.In-admission  mortality  13%  (10)  
Regarding  the  HIV  group,  only  12.5%  (7)  had  virological
suppression  and  none  had  immunological  response.  CD4  cell
count  mean  was  57  (0--458),  with  92%  (59)  below  200  cells.
Causes  of  immunodepression  in  the  non-HIV  group  were
mainly  due  to  drug  related  immunosuppression  (89%)  and
transplant  (74%)  (Table  2).
Clinically  there  was  a  statistically  signiﬁcant  difference
between  HIV  and  non-HIV  patients  in  relation  to  respiratory
complaints  (90%  vs  68%,  p-value  0.02).  This  difference  was
still  observed  after  adjusting  for  potential  confounders  (p-
value  0.04),  yielding  a  2.2  odds  ratio  (OR),  which  means  a  2.2
times  higher  risk  in  HIV  patients.  There  was  also  a  difference
between  groups  in  LDH  elevation  at  diagnosis  (73%  vs  40%,
p-value  0.001),  which  was  still  observed  after  adjusting  for
confounding,  with  a  1.7  times  higher  risk  in  HIV  patients.
There  was  no  statistically  signiﬁcant  difference  between
groups  in  the  presence  of  fever,  hypoxemia,  white  blood
count  abnormalities  and  C-reactive  protein  (Table  3).  Def-
inite  diagnosis  deﬁned  by  RT-PCR  isolation  of  P.  jirovecii  in
bronchoalveolar  lavage  (BAL)  material  was  similar  in  both
groups  (81%  vs  73%,  p-value  0.4).
In  terms  of  outcome  measures,  statistically  signiﬁ-
cant  differences  were  only  observed  in  need  for  invasive
mechanical  ventilation  (23%  vs  46%,  p-value  0.005)  and
in-hospital  mortality  (13%  vs  37%,  p-value  0.002).  Both
these  outcomes  were  still  statistically  signiﬁcant  following
adjustment  for  confounders  (p-values  of  0.015  and  0.037
respectively),  resulting  in  a  0.6  and  0.5  times  risk  for  inva-
sive  mechanical  ventilation  and  mortality  for  HIV  patients.
There  was  no  statistically  signiﬁcant  difference  in  the  need
for  corticotherapy  or  non-invasive  mechanical  ventilation
(Table  4).
H
m37%  (20)  23%  (30)  0.002
onclusion
he  results  show  that  the  populations  suffering  from  HIV  and
on-HIV  immunosuppression  are  different  in  terms  of  demo-
raphics,  with  HIV  patients  mostly  being  younger  and  of  the
ale  gender,  which  might  be  related  to  HIV  epidemiology.
The  main  causes  for  immunosuppression  in  our  cohort
re  drug  related  immunosuppression  and  transplant,  which
re  obviously  related,  but  also  include  autoimmune  patients
ndergoing  biological  immunosuppression.  This  largely  cor-
elates  to  our  hospital  setting  as  a  reference  center  for  both
olid  organ  transplant  and  autoimmune  disease  patients.
Clinically,  HIV  patients  were  more  exuberant  with  higher
ikelihood  of  experiencing  respiratory  complaints  and  of  hav-
ng  a  higher  LDH  level,  very  relevant  for  the  diagnosis.  On
he  contrary,  non-HIV  patients  were  mostly  likely  to  have
orse  outcomes  such  as  the  need  for  invasive  mechani-
al  ventilation  and  in-hospital  mortality.  Interestingly,  these
ad  outcomes  were  not  related  to  accuracy  of  diagnosis  or
emographic  variables  that  were  so  different  between  the
wo  groups.
The  results  suggest  that  the  clinical  presentation  in  non-
IV  patients  is  more  subtle,  but  with  worse  consequences
han  in  HIV  patients.  This  ﬁts  in  with  the  published  data.  It
emains  to  be  answered  if  these  two  ﬁndings  are  related,  and
o  if  the  higher  mortality  and  need  for  invasive  mechanical
entilation  are  a  result  of  a  later  diagnosis  due  to  an  elusive
linical  presentation.  Therefore,  it  would  be  interesting  toThis  work  has  some  confounders,  mainly,  that  the  non-
IV  group  was  not  very  representative,  being  composed
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